vs
Side-by-side financial comparison of Grand Canyon Education, Inc. (LOPE) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Grand Canyon Education, Inc. is the larger business by last-quarter revenue ($308.1M vs $158.6M, roughly 1.9× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 28.1%, a 43.0% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 5.3%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $122.9M).
Grand Canyon Education, Inc. (GCE) is an American for-profit corporation that provides services to universities, specializing in program development, online education, and operational support. Formerly affiliated with Grand Canyon University (GCU), a Christian university in Arizona, GCE became a separate publicly traded company in 2008.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
LOPE vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $308.1M | $158.6M |
| Net Profit | $86.7M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 35.1% | 70.2% |
| Net Margin | 28.1% | 71.2% |
| Revenue YoY | 5.3% | 3661.1% |
| Net Profit YoY | 5.9% | 528.0% |
| EPS (diluted) | $3.13 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $308.1M | — | ||
| Q3 25 | $261.1M | — | ||
| Q2 25 | $247.5M | — | ||
| Q1 25 | $289.3M | $158.6M | ||
| Q4 24 | $292.6M | $22.6M | ||
| Q3 24 | $238.3M | — | ||
| Q2 24 | $227.5M | — | ||
| Q1 24 | $274.7M | — |
| Q4 25 | $86.7M | — | ||
| Q3 25 | $16.3M | — | ||
| Q2 25 | $41.5M | — | ||
| Q1 25 | $71.6M | $112.9M | ||
| Q4 24 | $81.9M | $-10.5M | ||
| Q3 24 | $41.5M | — | ||
| Q2 24 | $34.9M | — | ||
| Q1 24 | $68.0M | — |
| Q4 25 | 35.1% | — | ||
| Q3 25 | 6.9% | — | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 30.4% | 70.2% | ||
| Q4 24 | 34.2% | -60.4% | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 18.8% | — | ||
| Q1 24 | 30.8% | — |
| Q4 25 | 28.1% | — | ||
| Q3 25 | 6.2% | — | ||
| Q2 25 | 16.8% | — | ||
| Q1 25 | 24.8% | 71.2% | ||
| Q4 24 | 28.0% | -46.4% | ||
| Q3 24 | 17.4% | — | ||
| Q2 24 | 15.3% | — | ||
| Q1 24 | 24.8% | — |
| Q4 25 | $3.13 | — | ||
| Q3 25 | $0.58 | — | ||
| Q2 25 | $1.48 | — | ||
| Q1 25 | $2.52 | $1.90 | ||
| Q4 24 | $2.83 | $-0.15 | ||
| Q3 24 | $1.42 | — | ||
| Q2 24 | $1.19 | — | ||
| Q1 24 | $2.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $111.8M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $746.9M | $350.1M |
| Total Assets | $992.3M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $111.8M | — | ||
| Q3 25 | $97.3M | — | ||
| Q2 25 | $192.3M | — | ||
| Q1 25 | $144.5M | $274.8M | ||
| Q4 24 | $324.6M | $128.0M | ||
| Q3 24 | $263.6M | — | ||
| Q2 24 | $241.3M | — | ||
| Q1 24 | $196.2M | — |
| Q4 25 | $746.9M | — | ||
| Q3 25 | $758.0M | — | ||
| Q2 25 | $778.0M | — | ||
| Q1 25 | $780.7M | $350.1M | ||
| Q4 24 | $783.9M | $229.0M | ||
| Q3 24 | $764.1M | — | ||
| Q2 24 | $759.2M | — | ||
| Q1 24 | $759.4M | — |
| Q4 25 | $992.3M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.0B | $406.9M | ||
| Q4 24 | $1.0B | $271.6M | ||
| Q3 24 | $992.9M | — | ||
| Q2 24 | $992.7M | — | ||
| Q1 24 | $1.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.5M | $131.8M |
| Free Cash FlowOCF − Capex | $122.9M | $131.7M |
| FCF MarginFCF / Revenue | 39.9% | 83.0% |
| Capex IntensityCapex / Revenue | 2.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.50× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $238.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.5M | — | ||
| Q3 25 | $-48.6M | — | ||
| Q2 25 | $124.0M | — | ||
| Q1 25 | $67.6M | $131.8M | ||
| Q4 24 | $135.8M | $-23.2M | ||
| Q3 24 | $-29.4M | — | ||
| Q2 24 | $98.6M | — | ||
| Q1 24 | $85.0M | — |
| Q4 25 | $122.9M | — | ||
| Q3 25 | $-58.3M | — | ||
| Q2 25 | $115.4M | — | ||
| Q1 25 | $58.7M | $131.7M | ||
| Q4 24 | $126.1M | $-23.2M | ||
| Q3 24 | $-39.0M | — | ||
| Q2 24 | $89.6M | — | ||
| Q1 24 | $76.0M | — |
| Q4 25 | 39.9% | — | ||
| Q3 25 | -22.3% | — | ||
| Q2 25 | 46.6% | — | ||
| Q1 25 | 20.3% | 83.0% | ||
| Q4 24 | 43.1% | -102.7% | ||
| Q3 24 | -16.3% | — | ||
| Q2 24 | 39.4% | — | ||
| Q1 24 | 27.7% | — |
| Q4 25 | 2.5% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.1% | 0.1% | ||
| Q4 24 | 3.3% | 0.2% | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 3.9% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.50× | — | ||
| Q3 25 | -2.99× | — | ||
| Q2 25 | 2.98× | — | ||
| Q1 25 | 0.94× | 1.17× | ||
| Q4 24 | 1.66× | — | ||
| Q3 24 | -0.71× | — | ||
| Q2 24 | 2.83× | — | ||
| Q1 24 | 1.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
